Functional Change With MMS (FMS)
Primary Purpose
Muscle Weakness
Status
Unknown status
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
The ZELTIQ System
Sponsored by
About this trial
This is an interventional other trial for Muscle Weakness
Eligibility Criteria
Inclusion Criteria
- Subject (healthy volunteer) has read and signed the study written informed consent form.
- Male or female ≥ 22 years and ≤65 years of age.
- Subject has not had weight change exceeding 5% of body weight in the preceding month.
- Subject agrees to maintain body weight within 5% during the study by not making any changes in diet or exercise routine during the course of the study.
- Subject has a BMI ≤ 30 as determined at screening.
- Subject agrees to have photographs taken of the treatment area(s) during the scheduled time periods.
- Subject agrees to refrain from any new abdominal muscle training exercises of the treatment area during the course of the study.
Exclusion Criteria
- Subject has had a recent surgical procedure(s) in the area of intended treatment and muscle contractions may disrupt the healing process.
- Subject needs to administer or has a known history of subcutaneous injections into the area of intended treatment (e.g., heparin, insulin) within the past month.
- Subject has had an intrauterine contraceptive device inserted or removed within the past month.
- Subject has a bleeding disorder or hemorrhagic condition
- Subject is taking or has taken diet pills or supplements within the past month.
- Subject has an active implanted electrical device such as a cardiac pacemaker, cochlear implant, intrathecal pump, hearing aids, defibrillator, or drug delivery system.
- Subject has metal or electronic implants in or adjacent to the treatment area
- Subject has an abdominal hernia.
- Subject has pulmonary insufficiency.
- Subject has a cardiac disorder.
- Subject has a malignant tumor.
- Subject has been diagnosed with a seizure disorder such as epilepsy.
- Subject currently has a fever.
- Subject is diagnosed with Grave's disease.
- Subject has a growth plate in the treatment area
- Subject is pregnant or intending to become pregnant during the study period (in the next 9 months).
- Subject is lactating or has been lactating in the past 6 months.
- Subject is unable or unwilling to comply with the study requirements.
- Subject is currently enrolled in a clinical study of any unapproved investigational device, investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study.
- Any other condition or laboratory value that would, in the professional opinion of the Investigator, potentially affect the subject's response or the integrity of the data or would pose an unacceptable risk to the subject.
Sites / Locations
- Innovation Research Center
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Muscle Toning
Arm Description
The treatments are designed to evaluate muscle toning, firming and strengthening in the abdomen and buttocks.
Outcomes
Primary Outcome Measures
Body Satisfaction Scale (BSS)
Change in subject perception of body shape using the Body Satisfaction Scale (BSS) at the 4-Week follow-up visit.
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04506502
Brief Title
Functional Change With MMS
Acronym
FMS
Official Title
Functional Changes With Magnetic Muscle Stimulation of Abdominal Muscle
Study Type
Interventional
2. Study Status
Record Verification Date
August 2020
Overall Recruitment Status
Unknown status
Study Start Date
August 3, 2020 (Actual)
Primary Completion Date
May 2021 (Anticipated)
Study Completion Date
May 2022 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Zeltiq Aesthetics
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Evaluate the safety and efficacy of magnetic muscle stimulation (MMS) of abdominal muscle.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Muscle Weakness
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
45 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Muscle Toning
Arm Type
Experimental
Arm Description
The treatments are designed to evaluate muscle toning, firming and strengthening in the abdomen and buttocks.
Intervention Type
Device
Intervention Name(s)
The ZELTIQ System
Intervention Description
The MMS device will be used to perform the treatments.
Primary Outcome Measure Information:
Title
Body Satisfaction Scale (BSS)
Description
Change in subject perception of body shape using the Body Satisfaction Scale (BSS) at the 4-Week follow-up visit.
Time Frame
4-wk follow up visit
10. Eligibility
Sex
All
Minimum Age & Unit of Time
22 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria
Subject (healthy volunteer) has read and signed the study written informed consent form.
Male or female ≥ 22 years and ≤65 years of age.
Subject has not had weight change exceeding 5% of body weight in the preceding month.
Subject agrees to maintain body weight within 5% during the study by not making any changes in diet or exercise routine during the course of the study.
Subject has a BMI ≤ 30 as determined at screening.
Subject agrees to have photographs taken of the treatment area(s) during the scheduled time periods.
Subject agrees to refrain from any new abdominal muscle training exercises of the treatment area during the course of the study.
Exclusion Criteria
Subject has had a recent surgical procedure(s) in the area of intended treatment and muscle contractions may disrupt the healing process.
Subject needs to administer or has a known history of subcutaneous injections into the area of intended treatment (e.g., heparin, insulin) within the past month.
Subject has had an intrauterine contraceptive device inserted or removed within the past month.
Subject has a bleeding disorder or hemorrhagic condition
Subject is taking or has taken diet pills or supplements within the past month.
Subject has an active implanted electrical device such as a cardiac pacemaker, cochlear implant, intrathecal pump, hearing aids, defibrillator, or drug delivery system.
Subject has metal or electronic implants in or adjacent to the treatment area
Subject has an abdominal hernia.
Subject has pulmonary insufficiency.
Subject has a cardiac disorder.
Subject has a malignant tumor.
Subject has been diagnosed with a seizure disorder such as epilepsy.
Subject currently has a fever.
Subject is diagnosed with Grave's disease.
Subject has a growth plate in the treatment area
Subject is pregnant or intending to become pregnant during the study period (in the next 9 months).
Subject is lactating or has been lactating in the past 6 months.
Subject is unable or unwilling to comply with the study requirements.
Subject is currently enrolled in a clinical study of any unapproved investigational device, investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study.
Any other condition or laboratory value that would, in the professional opinion of the Investigator, potentially affect the subject's response or the integrity of the data or would pose an unacceptable risk to the subject.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kerrie Jiang, NP
Organizational Affiliation
Zeltiq Aesthetics
Official's Role
Study Director
Facility Information:
Facility Name
Innovation Research Center
City
Pleasanton
State/Province
California
ZIP/Postal Code
94588
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Functional Change With MMS
We'll reach out to this number within 24 hrs